Understanding the complexity of abciximab-related thrombocytopenia

Raffaele De Caterina; Marco Zimarino

doi:10.1160/TH10-01-0016

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2010; 103(03): 484-486
DOI: 10.1160/TH10-01-0016

Editorial Focus

Schattauer GmbH

Understanding the complexity of abciximab-related thrombocytopenia

Autoren

Raffaele De Caterina

¹Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy
Marco Zimarino

¹Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy

Abstract

Volltext

Referenzen

References
1 Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 2008; 99: 253-263.
2 Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86: 427-443.
3 Bassand JP, Hamm CW, Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
4 Van de Werf F, Bax J, Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
5 Topol EJ, Moliterno DJ, Herrmann HC. et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-1894.
6 Berkowitz SD, Sane DC, Sigmon KN. et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998; 32: 311-319.
7 Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 1999; 61: 205-208.
8 Merlini PA, Rossi M, Menozzi A. et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004; 109: 2203-2206.
9 Tcheng JE, Kereiakes DJ, Lincoff AM. et al. Abciximab readministration: results of the ReoPro Read-ministration Registry. Circulation 2001; 104: 870-875.
10 Iakovou Y, Manginas A, Melissari E. et al. Acute profound thrombocytopenia associated with anaphylactic reaction after abciximab therapy during percutaneous coronary angioplasty. Cardiology 2001; 95: 215-216.
11 Curtis BR, Swyers J, Divgi A. et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054-2059.
12 Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127 (Suppl. 02) 53S-59S.
13 Iijima R, Ndrepepa G, Mehilli J. et al. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thromb Haemost 2007; 98: 852-857.
14 Gore JM, Spencer FA, Gurfinkel EP. et al. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2009; 103: 175-180.
15 Curtis BR, Divgi A, Garritty M. et al. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 2: 985-992.
16 Sane DC, Damaraju LV, Topol EJ. et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000; 36: 75-83.
17 Knight DM, Wagner C, Jordan R. et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995; 32: 1271-1281.
18 Persselin JE, Stevens RH. Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J Clin Invest 1985; 76: 723-730.
19 Bougie DW, Wilker PR, Wuitschick ED. et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100: 2071-2076.
20 Yoder M, Edwards RF. Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother 2002; 36: 628-630.
21 Rezkalla SH, Hayes JJ, Curtis BR. et al. Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovasc Interv 2003; 58: 76-79.
22 Mascelli MA, Lance ET, Damaraju L. et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680-1688.
23 Lajus S, Clofent-Sanchez G, Jais C. et al. Thrombocytopenia after abciximab use results from different mechanisms. Thromb Haemost 2010; 103: 651-661.
24 Nurden P, Poujol C, Durrieu-Jais C. et al. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Blood 1999; 93: 1622-1633.